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Abstract
Clinical trials are conducted to evaluate the efficacy of new treatments. Clinical trials in-
volving multiple treatments utilize randomization of the treatment assignments to enable
the evaluation of treatment efficacies in an unbiased manner. Such evaluation is performed
in post hoc studies that usually use supervised-learning methods that rely on large amounts
of data collected in a randomized fashion. That approach often proves to be suboptimal
in that some participants may suffer and even die as a result of having not received the
most appropriate treatments during the trial. Reinforcement-learning methods improve
the situation by making it possible to learn the treatment efficacies dynamically during
the course of the trial, and to adapt treatment assignments accordingly. Recent efforts
using multi-arm bandits, a type of reinforcement-learning methods, have focused on maxi-
mizing clinical outcomes for a population that was assumed to be homogeneous. However,
those approaches have failed to account for the variability among participants that is be-
coming increasingly evident as a result of recent clinical-trial-based studies. We present
a contextual-bandit-based online treatment optimization algorithm that, in choosing treat-
ments for new participants in the study, takes into account not only the maximization of the
clinical outcomes but also the patient characteristics. We evaluated our algorithm using a
real clinical trial dataset from the International Stroke Trial. The results of our retrospec-
tive analysis indicate that the proposed approach performs significantly better than either a
random assignment of treatments (the current gold standard) or a multi-arm-bandit-based
approach, providing substantial gains in the percentage of participants who are assigned
the most suitable treatments. The contextual-bandit and multi-arm bandit approaches
provide 72.63% and 64.34% gains, respectively, compared to a random assignment.
1. Introduction
A randomized clinical trial is the current gold-standard approach for evaluating treatment
efficacy. In such a setting, the participants are divided randomly into separate groups to
enable comparison of different treatments or other interventions. Since these trials usually
require large sample sizes and therefore long study durations, a large number of participants
receive suboptimal treatments, especially when multiple treatments are being evaluated in
a trial (Fuster et al., 2012; Cummings et al., 2014; Minnerup et al., 2014). Although some
information about the efficacies of treatments and their relation to patient characteristics is
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acquired during the course of these trials, this information is almost always underutilized.
That is a big limitation because, if correctly utilized, this information has the potential
to provide huge monetary savings and improved patient outcomes (Berry and Eick, 1995).
This paper introduces a decision-theoretic approach to address that limitation and shows
its utility in a real clinical trial dataset.
Several recent studies have proposed adaptive strategies for treatment administration in
clinical trials (Villar et al., 2015; Villar and Rosenberger, 2018). These approaches achieve
adaptability by utilizing a type of online reinforcement learning algorithms known as multi-
arm bandits (Gittins et al., 2011). Initial developments on multi-arm bandits occurred in the
context of gambling scenarios in which an agent had to choose an action that would maximize
the rewards, and the strategy (or policy) for choosing the actions was dynamically updated
during the game. That problem involved exploration/exploitation tradeoffs: there should
be a balance between trying different actions to learn more about their expected payouts,
and wanting to exploit the best action based on the information already obtained. Bandit
approaches employ different sampling strategies to effectively handle this tradeoff. In the
setting of a clinical trial, such an algorithm aims to identify a policy for assigning patients
into treatment subgroups in a way that maximizes favorable clinical outcomes while still
allowing the exploration of previously under-explored treatments.
Although the general approach of multi-arm bandits perfectly suits our goal, a limitation
of the prior studies utilizing this approach is that they do not account for the inter-patient
variability, e.g., how two patients may respond to the same treatment differently. Instead,
they consider all patients to be similar in the way they respond to treatments and they
therefore come up with a common dynamic policy for all new participants. There is increas-
ing evidence in the medical literature that patient populations are heterogeneous and that
individuals respond to treatments differently (Athreya et al., 2017). This phenomenon espe-
cially pronounced even more profound in complex neurological and cardiovascular diseases
for which the same clinical diagnosis might arise from different underlying pathological mech-
anisms (Molina-Porcel et al., 2008). Hence, an online learning algorithm that considered
disease-related characteristics of the participants in addition to the general multi-arm bandit
setting would be better suited for clinical trials. In this paper, we describe a contextual-
bandit-based approach that incorporates patient characteristics to refine treatment select in
clinical trials.
Contextual bandits (Li et al., 2010) are a generalization of multi-arm bandits in which the
policy for choosing future actions is dependent on the context of the game. In the setting of a
clinical trial, the context can be the disease-related characteristics of a new participant that
determine which of the treatments will be beneficial for that participant. From a different
perspective, the contextual-bandit approach attempts to dynamically stratify participants
based on their predispositions to treatment responses. We showcase the utility of this model
using a publicly available dataset collected during the International Stroke Trial (IST),
a clinical trial that evaluating the efficacies of two drug-based treatments in altering the
course of acute ischemic stroke (Carolei et al., 1997). We imitated the real-time scenario by
sequentially going through the data of each participant in the trial. Based on the treatment
given to each participant and the corresponding clinical outcome, we utilized our approach
to learn about and update our understanding of the relationship between contexts (i.e.,
patient characteristics), treatments, and clinical outcomes. Then we used that knowledge
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to choose treatments to administer to the next participant. We repeated that process until
the end of the trial and recorded the clinical outcomes resulted from our approach. The
results of this retrospective analysis indicate that the contextual-bandit-based approach
performs significantly better than a either random assignment of treatments (the current
gold standard) and a context-free multi-arm-bandit-based approach, providing substantial
gains in the percentage of participants who received the most suitable treatments. The
contextual-bandit and multi-arm bandit approaches provided 72.63% and 64.34% better
results, respectively, than the random assignment did.
2. Related work
There has been significant interest in developing adaptive strategies for clinical trials (Coffey
and Kairalla, 2008; Berry, 2010). Adaptive trials allow specific changes in key trial attributes
(e.g., sample size, the test statistic, or the outcome variable used to measure the treatment
effect) across the course of the trial based on information acquired during the trial (Pocock,
1977). However, most adaptive trials proposed in the past focused on evaluating a single
treatment in a single population (Freidlin and Simon, 2005). In addition, traditional de-
signs of adaptive strategies have primarily concentrated on the statistical attributes of the
trials and have neglected to consider the well-being of participants or the cost of ineffective
treatments.
Adaptive strategies that evaluate multiple treatments and combinations of treatments
have received interest recently (Villar et al., 2015; Villar and Rosenberger, 2018). Although
they take into account the well-being of participants and the cost of ineffective treatments,
these multi-arm-bandit-based approaches do not generalize to heterogeneous patient popu-
lations in which participants with similar medical conditions might respond to treatments
differently. Many recent posthoc studies of clinical trials have demonstrated that treatment
responses of individuals with similar clinical conditions vary based on their clinical and
biomarker profiles (Catenacci, 2015; Lazar et al., 2016; Marshall, 2014). Such recent reve-
lations necessitate context-aware strategies in adaptive clinical trials. A contextual-bandit
is a light-weight reinforcement learning approach that is suitable for learning behavior from
feedback when the behavior depends on external factors in addition to the stimuli (Littman,
2015). Contextual-bandit approaches have been successfully applied in recommender sys-
tems, where the recommendations to a specific user depend on the feedback given by the
user for the past recommendations as well as user-specific characteristics (Li et al., 2010,
2011). Our approach, to our knowledge, is the first to apply it on a clinical trial setting and
demonstrate its efficacy using a real clinical trial dataset.
3. Model description
Definitions: Consider a clinical trial involving K treatments.The context of patient i is
denoted by Xi ∈ RD, which is a vector consisting of D attributes related to the disease
being considered in the trial. We also use Ui to denote the treatment that was provided
to patient i, and Ci to denote the corresponding clinical outcome, where Ui is a discrete
random variable taking values in the set {1, . . . ,K}. In addition, we assume that the clinical
outcomes (Ci) can be dichotomized as successes or failures and model them as binary random
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variables, i.e., Ci ∈ {0, 1}. We are interested in choosing a treatment for each participant
of the trial based on his or her specific disease-related characteristics in order to maximize
the probability of successful recovery. We do so by using an online optimizer that involves
a learning component to learn from past information and a decision component to choose
optimal actions based on learned response patterns. That process is illustrated in figure 1.
Decision
Clinical trial
environment
Learning
Online optimizer
𝑋𝑖Participant 𝑖:
𝑈𝑖
𝐶𝑖
Figure 1: Illustration of the online optimizer used in a clinical trial setting.
Context-free setting: Here we will first formalize the problem for a setting that does not
take the context into account and then we will extend it to a contextual setting later in this
section. In the context-free setting, the outcomes depend only on the treatment provided.
Therefore, the outcomes can be seen as having been drawn from a Bernoulli distribution with
parameter θu, where θu denotes the success probability (or the mean reward) of treatment
U = u. The mean rewards θ = {θ1, . . . , θK} are unknown, but not time-varying.
Objective: Given the above definitions, our goal is to choose the treatments in such a way
that they are optimal for each patient. Suppose that the optimal treatment for patient i is
U?i and the corresponding outcome is C
?
i . Then, the objective of the online optimizer is to
minimize the following two quantities, where N denotes the total number of participants in
the study.
R =
N∑
i=1
[C?i − Ci] (1)
S =
N∑
i=1
[
IU?i 6=Ui
]
(2)
where I is the indicator function.
The first quantity R (also known as regret) measures the difference between the actual
outcomes from the optimal outcomes that would have been achieved had we identified the
correct treatment for each patient. The second quantity S (also known as the suboptimal
action count) measures the number of instances when the chosen treatment was not the
same as the correct treatment for a patient.
Model of the priors: In order to achieve the above goal, we are interested in learning the
correct priors for each treatment u, and utilizing those priors to choose treatments for the
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new participants in the study. We model the priors to be beta-distributed with parameters
α = {α1, . . . , αK} and β = {β1, . . . , βK}. Please note that the beta distribution is the
conjugate prior of the Bernoulli distribution. Then, for each treatment u, the probability
density function of θu is
p(θu) =
Γ(αu + βu)
Γ(αu)Γ(βu)
θαu−1u (1− θu)βu−1, (3)
where Γ denotes the Gamma distribution. We begin with an independent prior belief over
each θu, i.e., αu = βu = 1 for each u ∈ {1, . . . ,K}. With each new observation, (i.e., a
treatment (Ui), outcome (Ci) pair), the distribution is updated using Bayes’ rule. Because
of the conjugacy properties, the parameters αu and βu can be updated using the following
simple rule.
(αu, βu)←
{
(αu, βu) if Ui 6= u
(αu, βu)) + (Ci, 1− Ci) if Ui = u (4)
Note that a beta distribution with parameters (αu, βu) has the mean αu/(αu+βu), and that
the distribution becomes more concentrated as αu and βu become large. In general, this
formulation is known as the Bernoulli bandit.
Choosing the treatment for a new patient: Since θus are beta-distributed, a naive
choice of treatment for a new patient is the treatment whose prior has the largest mean,
i.e., Ui = arg maxu
[
αu
αu+βu
]
. Although that greedy approach is a valid choice, a downside is
its inability to balance the exploration/exploitation trade-off (Russo et al., 2017). Here we
describe two popular bandit algorithms for choosing the treatment for a new patient based
on the distributions of priors learned from past experiments. Both are extremely effective
in balancing exploration/exploitation trade-off.
Thompson sampling is a Bayesian approach (Agrawal and Goyal, 2012) that randomly
samples the success probabilities of treatments from their respective prior distributions and
selects a treatment with the maximum sample value. It is easy to see that the distributions
of the priors will be more spread at the beginning of the trial, and therefore that all the
treatments will be selected with similar probabilities. With more participants, the distri-
butions will become narrower and the treatments with higher rewards are more likely to be
selected. However, unlike the greedy case, treatments with low rewards will still be selected
with relatively low probabilities, because the approach uses samples drawn from the distri-
butions of success probabilities. In that way, the Thompson sampling algorithm effectively
balances the exploration/exploitation trade-off. This is illustrated for the Bernoulli bandit
case in Algorithm 1.
The Upper confidence bound (UCB) algorithm, on the other hand, is a frequentist
approach that uses point estimates of the success probabilities of treatments to choose
future treatments. It also uses an extra additive term (
√
lni
nu,i
, which is added to the point
estimates of the priors; see Algorithm 2) that is inversely proportional to the number of
times a particular treatment has been applied. This additive term is also a function of
the duration of the trial and establishes an upper confidence bound for the point estimate
(Auer, 2002). It starts by applying each treatment at least once and then chooses future
actions based on the upper confidence bounds of the treatment success probabilities. As
with the Thompson sampling approach, the distributions of the priors will be more spread
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at the beginning and will become progressively narrower. However, the UCB algorithm
handles the exploration/exploitation trade-off slightly differently. The confidence bound of
the treatments that have been previously under-explored will grow with the duration of the
trial and will eventually exceed the bounds of other treatments and therefore get a chance to
be applied to a new patient. However, the chance that the treatments with low rewards will
be applied will diminish and eventually vanish. This is illustrated for the Bernoulli bandit
case in Algorithm 2.
Algorithm 1 Thompson sampling
1: for i = 1, 2, . . . , do
2: for u ∈ {1, . . . ,K} do
3: Sample θˆu ∼ beta(αu, βu) . sample model
Ui = arg maxu θˆu . select and apply action
4: Apply Ui and observe Ci
5: (αUi , βUi)← (αUi , βUi) + (Ci, 1− Ci) . update distribution
Algorithm 2 Upper confidence bound (UCB)
1: for i = 1, 2, . . . ,K do
2: Apply treatment i . apply each treatment once
3: for i = K + 1,K + 2, . . . , do
4: for u ∈ {1, . . . ,K} do
5: Estimate θˆu =
[
αu
αu+βu
]
. estimate mean rewards
6: nu,i ← # of times treatment u has been applied so far
7: Ui = arg maxu
[
θˆu +
√
lni
nu,i
]
. select and apply action
8: Apply Ui and observe Ci
9: (αUi , βUi)← (αUi , βUi) + (Ci, 1− Ci) . update distribution
Contextual setting: So far, we have considered a setting in which the context of the
participant is ignored. However, many recent clinical trials have shown that treatment
responses are very much context-dependent. In this paper, we assume that the contexts Xi
are D-dimensional binary vectors resulting in 2D different contexts. But fortunately, unlike
the success probabilities of treatments, the contexts are observable. The success probabilities
of treatments are likely different in different contexts. We incorporate the contexts into our
approach by treating each context as a different context-free multi-arm bandit problem.
Therefore, when a new participant joins the trial, depending on the observed context, a
treatment will be chosen based on the context-free bandit problem that includes only the past
participants with that specific context. Alternatively, we can maintain 2D number of distinct
bandits (one for each context) and choose treatments based on the bandit corresponding to
the observed context. This is illustrated in Algorithm 3, in which MAB(m) denotes the
context-free multi-arm bandit associated with context m.
6
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Algorithm 3 Contextual bandit for clinical trial optimization
1: for m = 1, 2, . . . , 2D do . initialize all context-free bandits
2: MAB(m)←initialize context-free bandit()
3: for i = 1, 2, . . . , do
4: Xi ←observe context(patient i)
5: MAB? = MAB(Xi) . bandit associated with context Xi
6: Ui ←select treatment(MAB?) . select a treatment based on priors in MAB?
7: Apply Ui and observe Ci
8: update prior(Ui, MAB?) . update the prior of Ui in MAB?
4. Application of the model to International Stroke Trial (IST) database
Data: The International Stroke Trial (IST) was one of the largest randomized trials ever
conducted for acute stroke (Carolei et al., 1997). The IST dataset includes data on 19,435
patients with acute stroke, with 99% complete follow-up. For each randomized patient, the
variables assessed at randomization, at the early outcome point (14 days after randomization
or prior discharge), and at 6 months were collected. The primary outcomes that were
recorded in the study are death within 14 days and death or dependency at 6 months. The
aim of the trial was to establish whether early administration of aspirin, heparin, both, or
neither influenced the clinical course of acute ischemic stroke.
Background: Stroke is a major source of economic burden and personal hardship to those
afflicted. Each year, approximately 795,000 people in the United States suffer a stroke and
about 600,000 of them are the person’s first stroke (Rosamond et al., 2008). Unfortunately,
because of changing demographics and the fact that stroke is an age-related disease, the
prevalence is expected to increase, given the advancing age of the population. Stroke ac-
counts for 1 of every 19 deaths in the U.S., making it the third leading cause of death
(behind heart disease and cancer) and in fact it is the leading cause of long-term disability
in the U.S. (Rosamond et al., 2008). Stroke imposes a huge burden on the economy. The
total direct and indirect costs are more than $100 billion per year counting hospitalization,
transition care and rehabilitation care, physician expenditures, medications, ancillary staff
and home care, and therapy, as well as indirect costs such as loss of economic productivity
(Rosamond et al., 2008).
Ischemic strokes: Approximately 90% of all strokes are ischemic (Adams et al., 1993).
Ischemic strokes comprise a variety of conditions in which blood flow to part of the brain is
reduced, resulting in tissue damage or death, and is usually an acute process. It is extremely
critical to obtain timely medical help for ischemic stroke. Untreated ischemic strokes can
lead to fluid buildup, swelling, and bleeding in the brain, seizures, and permanent problems
with memory and understanding. In addition, there is a 5–17% risk that another stroke will
follow a transient ischemic stroke within three months (Adams et al., 2007). Furthermore,
there is substantial evidence that stroke patients with certain other co-morbidities, such
as atrial fibrillation, respond to certain types of treatments better than others (Paciaroni
et al., 2007). Therefore, it is necessary to obtain timely medical help and the right kind of
treatment to avoid additional complications. Hence, an adaptive clinical trial setting may
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make it possible to learn these complex relationships and provide patients with the right
kinds of treatments.
5. Experiments & Evaluation
Contextual bandit setting: Here we describe the steps we took to apply the contextual
bandit model we described in Section 3 to the clinical trial data from the International
Stroke Trial. The trial included drug treatments based on aspirin and heparin. Hence, there
were four different possible treatments reflecting the different combinations of the two drugs
that could have been administered, i.e., K = 4. In addition, we use the 2-week mortality of
the participants to determine clinical outcomes. We consider discharge of a participant from
the hospital alive within two weeks to mean the treatment was successful. As previously
explained in Section 4, another cardiovascular comorbidity, atrial fibrillation can modulate
the response to heparin-based treatments. Therefore, we use the binary variable representing
whether or not the participant had atrial fibrillation as the context in our algorithm.
Analytic scheme: We simulated the online setting by sequentially going through the dtaa
of each participant admitted to the trial. Two bandits (one for each context) were created,
with 4 choices of treatments. For a new participant in the trial, depending on the context,
one of the bandits was selected. Then, we took three different approaches to choose a
treatment: a) a random choice (i.e., the strategy currently used in clinical trial settings),
b) a Thompson sampling-based approach, and c) a UCB-based approach. It was difficult
to estimate the outcome for a treatment chosen by any of the three approaches when that
treatment was not the one actually performed in the real clinical trial for that participant.
To circumvent that issue, for each context, we used all the participants in the clinical trial
dataset who had the same context to obtain estimates of the success probabilities of each
treatment and used a Bernoulli sample generator to generate an outcome for each treatment.
Note that the success probabilities of each context were calculated separately by considering
only the participants with the same context. Those estimated outcomes were used to update
the prior distributions within the bandit corresponding to the context of each participant.
We repeated that process through the end of the trial and recorded the outcomes and the
chosen treatments for each approach. We also evaluated a context-free multi-arm-bandit-
based approach, using the same dataset, to showcase the benefits of our approach. In the
context-free case, we calculated the success probabilities for the Bernoulli sampler using the
whole clinical trial dataset in a context independent manner.
Evaluation: We utilized the two quantities defined in Section 3, i.e., regret and suboptimal
action count, to evaluate our approaches. Since we do not know what would have been the
optimal treatment for each participant, we chose the maximum of all the success proba-
bilities estimated using the whole dataset as the optimal outcome and the corresponding
treatment as the optimal treatment. In the context-free case all the participants had the
same optimal treatment and corresponding outcome; in the contextual case, the participants
in each context had a their own identified optimal treatment and a corresponding outcome.
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6. Results
Here we report the experimental results obtained using our contextual-bandit-based ap-
proach and a context-free multi-arm-bandit-based approach for the International Stroke
Trial database. We ran each approach 20 times to evaluate the variability of regrets and
suboptimal draw counts. Figure 2 shows the trend of cumulative regrets and suboptimal
draw counts with increasing number of participants in the trial. Figures 2a and 2b show
the cumulative regrets incurred in both the approaches when treatments were selected using
random assignment, the UCB approach, and Thompson sampling. The plots include the
mean regret values and the 25th percentile confidence intervals. Similarly, Figures 2c and 2d
show the number of suboptimal draws in each case, as previously described. Table 1 reports
the relative advantages of using the UCB approach and the Thompson sampling approach
instead of random assignment, to select new treatments in the context-free multi-arm bandit
and contextual-bandit cases. The relative advantages are illustrated as percentages of the
regrets and suboptimal draw counts that were incurred in each case, compared with the
random case. Note that the absolute regret values seen in Figures 2a and 2b are not com-
parable between the context-free and contextual approaches because they were calculated
using different ground-truths (context-free and contextual ground-truths). However, the
relative percentage improvements achieved using Thompson sampling and UCB approach,
compared with the random approach, are comparable (since they were normalized using the
respective random approaches).
Table 1: The relative advantages of using the UCB approach and Thompson sampling to
select new treatments, as opposed to using a random assignment, in the context-free multi-
arm-bandit and contextual-bandit cases. For instance, the first entry in the table means that
Thompson sampling incurs only 11.18±5% of the regret incurred using a random assignment.
Multi-arm bandit Contextual bandit
Thompson UCB Thompson UCB
Regret 11.18±5% 29.57±7% 11.03±3% 26.10±4%
Suboptimal draws 35.66±10% 64.79±13% 27.37±2% 44.78±3%
Significance: It appears from Figure 2 that both the UCB and Thompson sampling ap-
proaches perform significantly better than random assignment in both the contextual-bandit
and context-free multi-arm-bandit cases. Furthermore, the Thompson sampling approach
seems to perform considerably better than the UCB approach in all the cases. When the
contextual and the context-free cases are considered, Table 1 shows that the contextual
case provides significant gains in the suboptimal draw counts and marginal gains in the
regret value. Overall, our results indicate that the contextual-bandit-based approach that
incorporates patient characteristics into the algorithm used to choose treatments for new
participants in the study performs better than a context-free approach, is able to learn
the differential response to treatments depending on the context of the participant (in this
case whether or not the participant had atrial fibrillation) relatively quickly and provide
significant advantages in correctly choosing treatments.
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Figure 2: Regrets and suboptimal draw counts obtained using context-free multi-arm-bandit
and contextual-bandit approaches for the IST database. Treatments were selected using
random assignment, the UCB approach, and Thompson sampling. Plots include mean
values of regrets and suboptimal draw counts and 25th percentile confidence intervals.
7. Discussion
Many factors contribute to the difficulty of developing and testing new therapies, including
the difficulty of obtaining patient consent, variability in the standard of care, inadequate
patient recruitment rates, and delays between trial phases as drugs move from early dose-
finding to efficacy trials. An adaptive design is a statistical tool for accelerating drug de-
velopment. Recent U.S. Food and Drug Administration draft guidance defines an adaptive
design as a “prospectively planned opportunity for modification of one or more specified
aspects of the study design" based on interim analysis of a study (Silver Spring, 2010). The
term “prospective" means that modification is planned before data are examined in an un-
blinded manner. Prior to that definition, development of adaptive designs has a long and
varied history. The idea of adaptive randomization was introduced in the 1930s (Thomp-
son, 1933), sample size recalculation in the 1940s (Stein, 1945), sequential dose finding in
the 1950s (Robbins and Monro, 1951), and play-the-winner strategies and group-sequential
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methods in the 1960s (Zelen, 1969). However, there are costs associated with the use of
adaptive designs, and they are seldom made obvious in the literature.
Limitations and future work: Our work has several limitations. First, this is a ret-
rospective study, so the outcomes for treatments other than the ones actually provided to
participants are unknown. Therefore, a model to simulate those outcomes was necessary to
showcase the utility of our approach. The validity and comprehensiveness of the simulation
model that we used in this work are debatable, considering the many confounder variables
that might exist in a real scenario. Furthermore, we illustrated the utility of the model using
a known risk-factor (i.e., atrial fibrillation) that can modulate response to stroke treatments.
That significantly simplified our analyses because it reduced the number of contexts consid-
ered in our approach to two. However, in a real clinical trial setting, a myriad of clinical and
biomarker variables would typically be collected, and the context space that included all
these variables might explode. In addition, the number of participants required to achieve
statistically significant gains in the regret and suboptimal draw counts will grow exponen-
tially with the number of contexts in the model. Those are significant limitations that need
to be answered before this model can be translated to a real clinical trial setting. We plan
to investigate these limitations using function approximation methods that might eliminate
the need for using as many bandits as the number of contexts in our model.
8. Conclusion
In this paper, we presented a contextual-bandit-based online algorithm for optimizing treat-
ment assignments in clinical trials. Unlike prior approaches, our algorithm takes patient
characteristics into account in addition to the maximization of the clinical outcomes as
criteria to determine treatments for new participants in the study. We evaluated our al-
gorithm using a real clinical trial dataset from the International Stroke Trial. The results
of our retrospective analysis indicate that the contextual-bandit-based approach performs
significantly better than either a random assignment of treatments (the current gold stan-
dard) or a context-free multi-arm-bandit-based approach, providing substantial gains in the
percentage of participants who receive the most suitable treatments. Hence, our study es-
tablishes the feasibility of an adaptive clinical trial setting that takes into account patient
characteristics in adapting the trial attributes. The retrospective nature of the study and
the difficulties of extending the model to the large number of clinical and biomarker variables
collected in a clinical trial are some of the limitations of our approach, and future efforts
will address these limitations.
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